Navigation Links
Cytokinetics Reports Additional Clinical Trials Data for Ispinesib

by arresting mitosis and cell proliferation without impacting unrelated, normal cellular functions, thereby avoiding many of the toxicities commonly experienced by patients treated with existing anti-mitotic drugs.

About Cytokinetics

Cytokinetics is a biopharmaceutical company focused on the discovery, development and commercialization of novel small molecule drugs that may address areas of significant unmet clinical needs. Cytokinetics development efforts are directed to advancing multiple drug candidates through clinical trials to demonstrate proof-of-concept in humans, specifically in the areas of heart failure and cancer. Cytokinetics' cardiovascular disease program is focused to cardiac myosin, a motor protein essential to cardiac muscle contraction. Cytokinetics lead compound from this program, CK-1827452, a novel small molecule cardiac myosin activator, recently entered Phase II clinical trials for the treatment of heart failure in 2007. Under a strategic alliance established in 2006, Cytokinetics and Amgen Inc. plan to conduct research with activators of cardiac myosin in order to identify potential treatments for patients with heart failure. Amgen has obtained an option for the joint development and commercialization of CK-1827452 exercisable during a defined period, the ending of which is dependent on Cytokinetics conduct of further clinical trials of CK-1827452. Cytokinetics cancer program is focused on mitotic kinesins, a family of motor proteins essential to cell division. Cytokinetics is developing two novel drug candidates that have arisen from this program, ispinesib and SB-743921, each a novel inhibitor of kinesin spindle protein (KSP), a mitotic kinesin. Ispinesib has been the subject of a broad clinical trials program comprised of nine Phase II clinical trials as well as six Phase I or Ib clinical trials. Cytokinetics plans to conduct additional clinical trials with ispinesib and is conducting a Phase I/II trial of SB-74392
'"/>




Page: 1 2 3 4 5 6 7 8

Related medicine technology :

1. Cytokinetics Announces Non-clinical Data to be Presented at the 2007 AACR Annual Meeting
2. Corgenix Reports New Clinical Data Correlating AtherOx Technology With Vascular Disease
3. Cobalis Reports Phase III Trial Results for PreHistin in Seasonal Allergic Rhinitis
4. Cosmo Pharmaceuticals Reports Positive Preliminary Phase II/III Data with Rifamycin MMX in Infectious Diarrhea
5. Cytos Biotechnology Reports Results from Phase IIa Study with CYT003-QbG10 in Patients Suffering from Atopic Dermatitis
6. The European Myeloma Platform Reports New Survival data for Revlimid Presented at the International Myeloma Workshop in Greece
7. Cytochroma Reports Positive Phase I Clinical Data for CTA018 Injection
8. Speedel Reports Successful SPP635 Phase IIa Trial in Hypertension
9. Columbia Laboratories Reports Positive Results from Multi-dose Pharmacokinetic Study of Vaginally-administered Lidocaine
10. CytRx Reports Promising Data from Its Open-Label Extension Clinical Trial of Arimoclomol in ALS
11. Affymax Reports Phase 2 Clinical Dose Ranging Results of Once-Per-Month Hematide for the Treatment of Anemia

Post Your Comments:
(Date:11/23/2009)...RINCETON,N.J.,Nov.23/PRNewswire-FirstCall/--Pharma...lmentofCohort2,ledbyitspartnerRoche(SWX:ROG.VX;RO....ype1and4patientsintheongoingphase2btrialofRG7128,a...orthetreatmentofchronichepatitisCvirus(HCV)infecti...ndependentDataMonitoringCommittee(DMC)ofallavailab...
(Date:11/23/2009)...OVATO,Calif.,Nov.23/PRNewswire-FirstCall/--RaptorP... RPTP ),todayannouncedresultsfromaPhase2bclinicalt...trate("DRCysteamine")inpatientswithnephropathiccys...rsityofCalifornia,SanDiego("UCSD")GeneralClinicalR...okineticsandpharmacodynamicsofasingledoseofDRCyste...
(Date:11/23/2009)...LISOVIEJO,Calif.,Nov.23/PRNewswire-FirstCall/--Oce...als International(NYSE: VRX ),todayannouncedthatit...iniumbromide,anauthorizedgeneric(AG)versionofLibra...tstobeasignificantplayerintheLibrax®genericma...rtantdivisionofourU.S.businesswithitssuccessfullau...
Breaking Medicine Technology:Pharmasset Announces the Continued Enrollment of the Phase 2b Clinical Trial of RG7128 for the Treatment of Hepatitis C 2Pharmasset Announces the Continued Enrollment of the Phase 2b Clinical Trial of RG7128 for the Treatment of Hepatitis C 3Pharmasset Announces the Continued Enrollment of the Phase 2b Clinical Trial of RG7128 for the Treatment of Hepatitis C 4Raptor Pharmaceutical Completes DR Cysteamine Phase 2b Clinical Trial in Cystinosis 2Raptor Pharmaceutical Completes DR Cysteamine Phase 2b Clinical Trial in Cystinosis 3Raptor Pharmaceutical Completes DR Cysteamine Phase 2b Clinical Trial in Cystinosis 4Raptor Pharmaceutical Completes DR Cysteamine Phase 2b Clinical Trial in Cystinosis 5Oceanside Pharmaceuticals Announces Launch of Librax(R) AG 2U S Faces Shortage of Heart Surgeons 56866 1U S Faces Shortage of Heart Surgeons 56866 2U S Faces Shortage of Heart Surgeons 56866 3Physicians Coalition for Injectable Safety Urges Reporting of Suspected Illegal Solicitation or Use of Botox Restylane Radiesse and Others 56864 1Physicians Coalition for Injectable Safety Urges Reporting of Suspected Illegal Solicitation or Use of Botox Restylane Radiesse and Others 56864 2Physicians Coalition for Injectable Safety Urges Reporting of Suspected Illegal Solicitation or Use of Botox Restylane Radiesse and Others 56864 3CBS Radio Presents Cars for Courage Boat Drive Sept 13 56861 1CBS Radio Presents Cars for Courage Boat Drive Sept 13 56861 2
(Date:11/23/2009)...3/PRNewswire/--XiotechCorporationtodayannouncedtha...TM)7000storagesystem,poweredbyIntelligentStorageEl...orageneeds,enablefuturegrowthanddeliversignificant...enter. ,, MasonGeneral,locatedinShelton,Wash.,w...,s"MostWired-Rural"hospitalsin2008and2009foritssup...
(Date:11/23/2009)...lants need longer-term support than most friends, ..., according to a study of 160 patients published i...dvanced Nursing . , Researchers surveyed 55 ...r, together with 105 who had had surgery in the la... Center in Tennessee, USA. They wanted to see if t...
(Date:11/23/2009)...ically modified to produce bacterial proteins that..., have been planted on more than 200 million hecta...amed after the bacterium Bacillus thuringiensis ,..., allowing farmers to save money and lessen enviro... However, since insects can evolve resistance to ...
(Date:11/23/2009)...t explain why more blacks die than whites, study f...) -- Body weight and co-existing health problems d...lower survival rates than whites, U.S. researchers...ve lower survival rates than whites for nearly all...ave explored a variety factors, such as difference...
(Date:11/23/2009)...nn.,Nov.23/PRNewswire/--HealthLeaders-InterStudy,a...ortsthatself-insuredmembercompaniesthatarepartofMi...ggregatehealthcare-costdecreaseof1.5percentperheal...high-performanceprovidernetwork.Accordingtothe Mil...nsuredmembercompaniessaved$44millioninhealthcareco...
Breaking Medicine News(10 mins):Health News:ISE Technology by Xiotech Helps Hospital Achieve Data Center Efficiency, Savings 2Health News:Drug side effects a key factor in reduced quality of life for kidney transplant patients 2Health News:Drug side effects a key factor in reduced quality of life for kidney transplant patients 3Health News:Insect resistance to Bt crops can be predicted, monitored and managed 2Health News:Weight May Not Drive Racial Disparities in Colon Cancer 2Health News:Milwaukee Employers See Cost Savings with High-Performance Provider Network 2
...nc. (Nasdaq:,ICAD), an industry-leading provider o... early identification of cancer, today announced t... with the private equity,firm, Welsh, Carson, Ande...mber of directors to eight. Mr. Ecock, age,46, bri...
... with New President, Congress on,Public-Private Ef...h Care,Payment Systems to Emphasize Wellness, Evid... of chief,executives from many of the nation,s lea...th care gap, between the status,quo and the ,healt...
...] Scientists at the Swedish medical university Kar...n that a receptor called ALK7 plays important role... as the release of insulin from beta-cells in the ...moving the ALK7 receptor improves insulin release ...
...ess Releases its 2007 Claims Review from,Leading I...ion Data,, PORTLAND, Maine, May 13 Data from the...d today by the Council for,Disability Awareness (C...ng-term disabilities has grown four times,the grow...
...-PRNewswire-FirstCall/ -- China Sky One,Medical, I...C Bulletin,Board: CSKI), a leading fully integrate...e-counter drugs in the People,s Republic of China,...aldorf Astoria in New York City., Mr. Yanqing Liu...
... Promising results from a team of NewYork-Presbyte...an-scientists show that gene therapy is both safe ... disease, or Late Infantile Neuronal Ceroid Lipofu...rial found that the procedure -- which involves in...
Other Medicine News:Health News:iCAD, Inc. Appoints Anthony F. Ecock to Board of Directors 2Health News:CEOs From Multiple Health Industries Announce Consensus Plan to Reform U.S. Health Care 2Health News:CEOs From Multiple Health Industries Announce Consensus Plan to Reform U.S. Health Care 3Health News:Novel mechanisms controlling insulin release and fat deposition discovered 2Health News:New Data Shows Continued Growth of Long-Term Disability Claims and Decline in Social Security Disability Insurance Applications Approval Rate 2Health News:New Data Shows Continued Growth of Long-Term Disability Claims and Decline in Social Security Disability Insurance Applications Approval Rate 3Health News:China Sky One Medical, Inc. to Present at Brean Murray Carret & Co. All-Cap All-China Conference 2Health News:NYP/Weill Cornell gene therapy clinical trial yields promising results for Batten disease 2
...ference laboratory and a worldwide leader in innov...fers an extensive test menu of highly complex and ...ology. Owned by the University of Utah, ARUP Labor...ion's university teaching hospitals and children's...
...ference laboratory and a worldwide leader in innov...fers an extensive test menu of highly complex and ...ology. Owned by the University of Utah, ARUP Labor...ion's university teaching hospitals and children's...
...ference laboratory and a worldwide leader in innov...fers an extensive test menu of highly complex and ...ology. Owned by the University of Utah, ARUP Labor...ion's university teaching hospitals and children's...
...ference laboratory and a worldwide leader in innov...fers an extensive test menu of highly complex and ...ology. Owned by the University of Utah, ARUP Labor...ion's university teaching hospitals and children's...
Medicine Products: